Search Results for “research” – Page 49 – media

Rubicon WIPI Axis Regulates Extracellular Secretion Synthesis during Aging Process

picture Writing | Sister Xian Extracellular vesicles are important mediators of intercellular communication, consisting of small vesicles with diameters ranging from 30-150 nanometers. They can transport biomolecules such as proteins, lipids, and nucleic acids from one cell to another, thereby regulating the behavior of recipient cells. Due to their roles in various physiological and pathological processes, extracellular vesicles have become a hot topic in biomedical research. Studies have found that as age increases, the number and composition of circulating extracellular vesicles change, which may have significant impacts on the aging process. The changes in miRNA and other molecules in extracellular vesicles with age may affect cell function and tissue regeneration ability [1]. However, how extracellular vesicles change during aging and the molecular mechanisms behind these changes are currently not fully understood. The formation of extracellular vesicles is a complex multi-step process involving the endosomal pathway and the biological formation of ...
- Source: drugdu
- 80
- September 20, 2024
Novo Nordisk’s new anchor

In the first half of 2024, Novo Nordisk achieved revenue of 133.4 billion Danish kroner, a year-on-year increase of 24%, and its performance continued to grow. The increase in the volume of semaglutide is a key factor in the growth of performance. Ozempic, a semaglutide hypoglycemic injection, achieved revenue of 56.7 billion Danish kroner, Rybelsus, a semaglutide hypoglycemic oral agent, achieved revenue of 10.9 billion Danish kroner, and Wegovy, a semaglutide weight loss injection, achieved revenue of 21 billion Danish kroner. The total sales of semaglutide were 88.7 billion Danish kroner, a year-on-year increase of 43%, accounting for 2/3 of Novo Nordisk’s total revenue. While semaglutide is selling well around the world, Novo Nordisk is also constantly adjusting and optimizing its R&D strategy and business layout. By enriching its product portfolio, it will further strengthen its dominant position in the field of blood sugar and fat reduction. At the same ...
- Source: drugdu
- 58
- September 20, 2024
Pneumonia Vaccine Price War Erupted

A price war has erupted for pneumonia vaccines, with pharmaceutical companies attempting to exchange lower prices for market share. Recently, public resource trading center websites in several provinces, including Jilin and Jiangsu, have shown that Zhifei Biological’s wholly-owned subsidiary, Zhifei Lvzhu, has reduced the price of its 0.5ml, 23-valent pneumococcal polysaccharide vaccine from 298 yuan to 209 yuan, a decrease of nearly 30%. This follows a series of price cuts for other vaccines, such as the HPV and flu vaccines, marking yet another manufacturer proactively lowering vaccine supply prices. Will other manufacturers follow suit? Watson Bio recently disclosed in a research announcement that the price of its 23-valent pneumonia vaccine has remained stable since its market introduction. Currently, the nationwide average winning bid price is lower than the adjusted prices of its competitors, and the company hopes to maintain price stability for its related products. Zhifei Biological’s 23-valent pneumococcal polysaccharide ...
- Source: drugdu
- 67
- September 20, 2024
Metformin, new role discovered

On September 12, a research team from the Chinese Academy of Sciences published a result in the journal Cell, titled “Metformin decelerates aging clock in male monkeys.” After eight years of in-depth research, its findings were confirmed in primates. Metformin can significantly delay aging, especially protecting the brain cognitive function of elderly animals. This study found that the protective effect of metformin on primate aging does not depend on its traditional blood sugar and metabolic regulatory functions, but will reset the intrinsic program of cellular aging, thereby delaying cellular aging. Previously, in a research report titled “Metformin facilitates viral reservoir reactivation and their recognition by anti-HIV-1 envelope antibodies” published in the international magazine iScience, scientists from the University of Montreal and other institutions found through research that metformin may help HIV-infected people who are receiving treatment clear the reservoir of the virus in their bodies and eventually eliminate the virus. ...
- Source: drugdu
- 55
- September 20, 2024
How many drugs does Biotech need to sell to avoid losing money?

Looking around the world, biotech is a group with extremely high “metabolism”. According to statistics from GF Securities, since 1990, more than 600 biotech companies have IPOed on Nasdaq. However, as of June 30, 2020, only 12 biotechs have relatively stable income and positive cash flow. Extending the timeline, from the rise of the concept of biotech in the 1980s to the present, in 40 years, there are only a few who have entered the pharma camp by buying on their own. Why is it difficult for biotech to survive for a long time? This is determined by the business model. Compared with large pharmaceutical companies with average growth but strong certainty, biotech is a divergent innovation model, and the growth process is full of uncertainty. In other words, due to the high risk of R&D and the uncertainty of sales, most biotechs can’t run the business model at all, ...
- Source: drugdu
- 59
- September 20, 2024
Andon Health has a tendency to invest in unmanned aerial vehicle medical transportation

According to the Qichacha APP, Tianjin Jiuyin Electronic Technology Co., Ltd. was recently established, with Li Kang as the legal representative and a registered capital of 500000 yuan. Its business scope includes: sales of satellite mobile communication terminals; Sales of navigation terminals; Sales of wearable smart devices; Sales of intelligent unmanned aerial vehicles, etc. Qichacha’s equity penetration shows that the company is wholly owned by Andon Health. In the field of medical applications, the “low altitude+medical rescue” unmanned aerial vehicle comprehensive solution has achieved normalized low altitude medical transportation services in multiple provinces and cities across the country. With the help of unmanned aerial vehicle technology, it innovates three key medical logistics scenarios: blood transportation, medical material distribution, and rapid response to emergency supplies. Will Jiu’an be involved in this direction in the future? Worth paying attention to. Has launched multiple wearable products, with asset management becoming one of its ...
- Source: drugdu
- 66
- September 19, 2024
Clinical study of innovative gene therapy drug LY-M003 injection launched

LY-M003 Disclaimer: Due to limited proficiency, errors are inevitable, or some information may not be timely. Please feel free to leave a message to indicate. This article only provides an introduction to medical and health-related drugs, and does not recommend treatment plans (if applicable); This article does not constitute any investment advice. Recently, a prospective, single center, open label, single arm, single dose clinical study evaluating the safety, tolerability, and efficacy of LY-M003 injection in the treatment of adult patients with Wilson’s disease was launched at the First Affiliated Hospital of Zhejiang University School of Medicine (hereinafter referred to as “Zhejiang First Hospital”). The project was led by Professor Yu Chaohui, the leader of the Gastroenterology Department, as the main researcher. LY-M003 injection is an innovative gene therapy drug developed by Lingyi (Hangzhou) Biotechnology Co., Ltd. (hereinafter referred to as “Lingyi Biotechnology”). The Department of Gastroenterology at Zhejiang First Hospital ...
- Source: drugdu
- 99
- September 19, 2024
Chinese non-opioid long-acting analgesics “break through one after another”

Recently, Kelun Pharmaceutical announced that its subsidiary Hunan Kelun Pharmaceutical’s chemical drug “Bupivacaine Liposome Injection” was approved for marketing by the National Medical Products Administration (trade name Bruco®), which was approved according to Class 3 chemical drugs and deemed to have passed the generic drug quality and efficacy consistency evaluation. Kelun Pharmaceutical’s Bruco® is the second bupivacaine liposome injection product to be launched in China. Hengrui Medicine’s bupivacaine liposome injection generic drug (trade name: Aihengping) was approved in November 2022. It is the world’s first generic drug and also the first long-acting postoperative analgesic drug to be launched in China. In July this year, Aihengping was approved for marketing by the FDA, becoming the world’s first manufacturer to obtain generic drug approval for this variety in the United States. Behind the successful breakthroughs of domestic pharmaceutical companies is the growing market demand in the field of long-acting postoperative analgesic preparations ...
- Source: drugdu
- 66
- September 19, 2024
The development of the new OTC market failed miserably! 5 points of retrospective thinking

The announcement of the complete closure of Shenzhen Zhonglian Pharmacy also announced that this once top 100 chain in the country could not withstand the economic downturn and collapsed. It also brought back the author’s memories of developing a new OTC market in Shenzhen many years ago. Shenzhen, the forefront of China’s reform and opening up, the first special economic zone, is not only the “holy land” in the hearts of countless businessmen, but also the place where miracles are born. In August 2001, I was sent to Shenzhen by the company to develop the market due to my outstanding performance at the age of 25. At that time, the company where the author worked was mainly engaged in women’s products (sanitary napkins, panty liners), and its business scope was mainly in the southwest region. Based on the concept of increasing the added value of women’s care products, it developed ...
- Source: drugdu
- 61
- September 19, 2024
The Heyuan Hemei Regenerative Medicine Center has been officially established, and Heyuan Biotech is embarking on a new journey with the wind

On September 13th, as the autumn atmosphere grew stronger, the establishment ceremony of Heyuan Hemei Regenerative Medicine Center was successfully held at 3888 Canghai Road and Heyuan Intelligent Manufacturing Precision Medical Industry Base in Lingang New Area, Shanghai. At the event, all the guests gathered together to witness this milestone moment.The successful holding of the establishment ceremony of Heyuan and Hemei marks a further expansion of Heyuan Group’s business map and a solid step forward in the strategic layout of cell therapy. As a high-tech enterprise deeply involved in the fields of cell and gene therapy, Heyuan Group relies on its own nearly 5000 square meters of comprehensive research and development production platform, as well as nearly 80000 square meters of port base, to continuously accelerate the research and commercialization process of cell and gene therapy. The establishment of Heyuan Hemei Regenerative Medicine Center will help enterprises build a more ...
- Source: drugdu
- 70
- September 18, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.